5346-53-2

Usage

Uses

Used in Pharmaceutical Industry:
5-AMINO-4-CYANO-1-(2-HYDROXYETHYL)PYRAZOLE is used as a key component in the development of new drugs and medicines. Its unique structure with both an amino and a cyano group allows for versatile interactions with biological targets, contributing to its potential as a therapeutic agent.
Used in Organic Synthesis:
In the field of organic synthesis, 5-AMINO-4-CYANO-1-(2-HYDROXYETHYL)PYRAZOLE serves as a building block for the production of various other chemical compounds. Its functional groups enable it to participate in a range of chemical reactions, facilitating the synthesis of diverse molecules with potential applications in various industries.
Used in Drug Discovery and Development:
Due to its potential biological activity and pharmacological properties, 5-AMINO-4-CYANO-1-(2-HYDROXYETHYL)PYRAZOLE is a target for further research in drug discovery and development. Its unique structural features make it a promising candidate for the creation of novel therapeutic agents that could address unmet medical needs.

InChI:InChI=1/C6H8N4O/c7-3-5-4-9-10(1-2-11)6(5)8/h4,11H,1-2,8H2

Upstream product

• 109-84-2 2-hydroxyethylhydrazine 
• 123-06-8 Ethoxymethylenemalononitrile 

Downstream Products

• 100524-24-1 9-(2'-hydroxyethyl)adenine 
• 58046-52-9 5-amino-1-(2-hydroxy-ethyl)-1H-pyrazole-4-carboxylic acid amide 
• 1361960-72-6 6-(difluro-(4-fluorophenyl)methyl)-N-(5-methyl-1H-pyrazol-3-yl)-1-(2-morpholinoethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 1361961-41-2 1-(2-chloroethyl)-6-(difluro-(4-fluorophenyl)-methyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ol 
• 1361960-73-7 6-(difluro-(4-fluorophenyl)methyl)-N-(5-methyl-1H-pyrazol-3-yl)-1-vinyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 1361961-43-4 1-(2-chloroethyl)-6-(difluro-(4-fluorophenyl)methyl)-N-(5-methyl-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 1362165-26-1 2-{4-amino-6-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}ethanol 
• 6714-29-0 2,3-dihydro-1H-imidazo[1,2-b]pyrazole 
• 89466-60-4 1-(2-chloroethyl)-5-amino-4-cyanopyrazole 
• 174648-63-6 7-<β-(benzyloxy)ethyl>-2-(2-furyl)pyrazolo<4,3-e>-1,2,4-triazolo<1,5-c>pyrimidine 
• 174648-72-7 5-amino-1-<β-(benzyloxy)ethyl>-4-<3-(2-furyl)-1,2,4-triazol-5-yl>pyrazole 

Relevant academic research and scientific papers

TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS

The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula (I): wherein W, X, Y, Z, R1, R2, R5, and R8 are as described herein.

AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF

Provided herein are azolopyridine and azolopyrimidine compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.

Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives: Potent and selective A2A adenosine antagonists

A series of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives (10a-o,q,r), bearing alkyl and aralkyl chains on positions 7 and 8, were synthesized in the attempt to obtain potent and selective antagonists for the A2A adenosine receptor subtype. The compounds were tested in binding and functional assays to evaluate their potency for the A2A compared with the A1 adenosine receptor subtype. In binding studies in rat brain membranes, most of the compounds showed affinity for A2A receptors in the low nanomolar range with a different degree of A2A versus A1 selectivity. Comparison of N7 (10a-d,h-o)- and N8 (10e-g)-substituted pyrazolo derivatives indicates that N7 substitution decreases the A1 affinity with the concomitant increase of A2A selectivity. Specifically, the introduction of a 3-phenylpropyl group at pyrazolo nitrogen in position 7 (101) increased significantly the A2A selectivity, being 210-fold, while the A2A receptor affinity remained high (Ki = 2.4 nM). With regards to the affinity for A2A receptors, also the compound 10n, bearing in the 7-position a β-morpholin-4-ylethyl group, deserves attention (K1 = 5.6 nM) even though the A2A selectivity (84-fold) was not as high as that of 101. Conversely, the compound 10m (N7-4-phenylbutyl derivative) showed a remarkable selectivity (A1/A2A ratio = 129) associated with lower A2A affinity (K1 = 21 nM). In functional studies, most of the compounds examined reversed 5′-(N-ethylcarbamoyl)adenosine-induced inhibition of rabbit platelet aggregation inhibition which is a biological response mediated by the A2A receptor subtype. The compounds are potent and selective A2A antagonists which can be useful to elucidate the pathophysiological role of this adenosine receptor subtype. These compounds deserve to be further developed to assess their potential for treatment of neurodegenerative disorders such as Parkinson's disease.

Pyrazolo[3,4-b]pyrrolo[3,4-e]pyridine-5(1H)-one and 1-H-pyrazolo[3,4-b][1,6]naphthyridine-5(6H)-one derivations, useful as anti-anxiety agents

Novel pyrazolo[3,4-b]pyridine lactams which are useful as anxiolytics are disclosed including methods of preparation, pharmaceutical compositions containing them and intermediates used in their preparation.

Pyrazolopyridine cycloalkanones and process for their preparation

Novel tetrahydropyrazolo-[3,4-b]quinolinones, cyclopenta[b]pyrazolo-[4,3-e]pyridinones and cyclohepta[b]-pyrazolo[4,3-e]pyridinones, useful as anxiolytics having reduced side effects, are disclosed, including methods of preparation, pharmaceutical compositions containing them and intermediates used in their preparation.